24小时热门版块排行榜

>论坛更新日志 (4628)
>导师招生 (340)
>文献求助 (340)
>休闲灌水 (219)
>论文投稿 (200)
>虫友互识 (136)
>博后之家 (125)
>考博 (118)
>学术会议 (102)
>教师之家 (52)
>找工作 (47)
>硕博家园 (43)
>公派出国 (42)
>招聘信息布告栏 (41)
>绿色求助(高悬赏) (37)
>考研 (35)

返回列表

【奖励】本帖被评价40次，作者york6999增加金币 31.8 个

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

york6999

木虫之王 (知名作家)

应助: 74 (初中生)
贵宾: 0.12
金币: 51320.3
帖子: 5655
在线: 1103.8小时
虫号: 781955

[资源] Antibiotic Pharmacodynamics

Antibiotic Pharmacodynamics
Editors: Rotschafer, John C., Andes, David R., Rodvold, Keith A. (Eds.)
Humana Press
March 30 2016
ISBN-10: 1493933213

Forges a path toward new antibiotic development processes for licensing new antibiotics
Offers state-of-the-art contributions from world renowned experts
Explores how antibiotics might be optimally used in a clinical situation
Features practical, reproducible methods and key implementation advice

This text offers state of the art contributions written by world renown experts which provide an extensive background on specific classes of antibiotics and summarize our understanding as to how these antibiotics might be optimally used in a clinical situation. The book explores pharmacodynamics methods for anti-infective agents, pharmacodynamics of antibacterial agents and non-antibacterial agents, as well as pharmacodynamic considerations and special populations. As part of the Methods in Pharmacology and Toxicology series, chapters include detailed insight and practical information for the lab.
Comprehensive and cutting-edge, Antibiotic Pharmacodynamics serves as an ideal reference for scientists investigating advances in antibiotic pharmacodynamics now finding their way into the antibiotic development process used for licensing new antibiotics.

Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
PART I PHARMACODYNAMICS METHODS FOR ANTI-INFECTIVE AGENTS
1 General Concepts of Pharmacodynamics for Anti-infective Agents . . . . . . . . . 3
Johan W. Mouton
2 In Vitro Pharmacodynamic Models to Evaluate Anti- infective
Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Warren Rose
3 Animal Models to Evaluate Anti-infective Pharmacodynamics . . . . . . . . . . . . 59
Alexander J. Lepak and David R. Andes
4 Pharmacodynamic Issues in Antibiotic Combinations . . . . . . . . . . . . . . . . . . 89
Zackery P. Bulman , Ryan C. Dillon , and Brian T. Tsuji
5 Methodologies for Protein Binding Determination
in Anti- infective Agents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Jatinder Kaur Mukker , Ravi Shankar Prasad Singh ,
and Hartmut Derendorf
6 Evaluation of Exposure-Response Relationships Using Clinical Data:
Basic Concepts and Applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
Sujata M. Bhavnani , Christopher M. Rubino , and Paul G. Ambrose
7 Toxicokinetics and Toxicodynamics of Anti-infective Agents . . . . . . . . . . . . . 159
David E. Nix
PART II PHARMACODYNAMICS OF ANTIBACTERIAL AGENTS
8 Pharmacodynamics of Fluoroquinolones . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
Ramy H. Elshaboury, Thomas J. Dilworth, and John C. Rotschafer
9 Aminoglycoside Pharmacodynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199
Dana R. Bowers , Amy N. Schilling , and Vincent H. Tam
10 Polymyxin Pharmacokinetics and Pharmacodynamics . . . . . . . . . . . . . . . . . . 221
Soon-Ee Cheah , Jian Li , Phillip J. Bergen , and Roger L. Nation
11 Vancomycin Pharmacodynamics: Optimal vs. Controversial . . . . . . . . . . . . . . 261
Ben M. Lomaestro
12 Pharmacodynamics of Lipoglycopeptides. . . . . . . . . . . . . . . . . . . . . . . . . . . . 285
Eric Wenzler , Siyun Liao , and Keith A. Rodvold
13 Pharmacodynamics of Daptomycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317
Eric Wenzler , Siyun Liao , and Keith A. Rodvold
14 Pharmacodynamics of Macrolides, Azalides, and Ketolides. . . . . . . . . . . . . . . 345
Wonhee So and David P. Nicolau
PART III PHARMACODYNAMICS OF NON-ANTIBACTERIAL AGENTS
15 Antifungal Pharmacokinetics and Pharmacodynamics . . . . . . . . . . . . . . . . . . 369
William Hope and David R. Andes
16 Pharmacokinetics and Pharmacodynamics of the Tuberculosis Drugs. . . . . . . 385
Aline B. Barth , Eric F. Egelund , and Charles A. Peloquin
17 Pharmacodynamics of Antimalarial Agents. . . . . . . . . . . . . . . . . . . . . . . . . . . 415
Rahul P. Bakshi and Theresa A. Shapiro
18 Pharmacodynamics of Antiviral Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 441
Renee- Claude Mercier , Bernadette Jakeman , and Larry Pineda
19 Pharmacodynamics of Antiretroviral Agents. . . . . . . . . . . . . . . . . . . . . . . . . . 469
Kajal B. Larson and Edward P. Acosta
PART IV PHARMACODYNAMIC CONSIDERATIONS AND SPECIAL POPULATIONS
20 Implementing a Continuous or Prolonged Infusion
Beta- Lactam Program in the Hospital Setting . . . . . . . . . . . . . . . . . . . . . . . . 507
Shawn H. MacVane , Nathaniel J. Rhodes , Marc H. Scheetz ,
and Joseph L. Kuti
21 Pharmacodynamic Considerations in Critically Ill Patients . . . . . . . . . . . . . . . 537
Mahipal G. Sinnollareddy and Jason A. Roberts
22 Pharmacodynamic Considerations and Special Populations: Pediatrics . . . . . . 561
Jennifer Le and John S. Bradley
23 Pharmacodynamics and Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 599
Manjunath P. Pai
24 Drug Development Process and Regulatory Science . . . . . . . . . . . . . . . . . . . 621
Evelyn J. Ellis-Grosse and Jogarao Gobburu
25 Antibiotic Stewardship and Applications of Pharmacodynamics . . . . . . . . . . . 633
Elizabeth D. Hermsen and Lynne Fehrenbacher
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 649